Drug Trial Radar · NCT05608291
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,564
Actual
Start
Jan 16, 2023
Primary completion
Jan 15, 2027
Study completion Apr 3, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life.
Conditions
- Melanoma
Interventions
FianlimabDrug
Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
CemiplimabDrug
Cemiplimab will be administered by IV infusion Q 3 weeks
PembrolizumabDrug
Pembrolizumab will be administered by IV infusion Q 3 weeks
PlaceboDrug
Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relapse free survival (RSF)Time frame: Up to 5 Years
Locations
211 sites in 22 countries. Site status is shown where the registry gives one.
UC San Diego
La Jolla, California
UCSF Medical Center at Mission Bay
San Francisco, California
John Wayne Cancer Institute (JWCI)
Santa Monica, California
The Melanoma And Skin Cancer Institute
Englewood, Colorado
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida
Orlando Health
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
Northwestern University
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Columbia University
New York, New York
University of Rochester
Rochester, New York
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Duke Cancer Institute, University Hospital
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
The Ohio State University James Comprehensive Cancer Center
Columbus, Ohio
St Lukes University Health Network
Easton, Pennsylvania
University Of Pittsburgh
Pittsburgh, Pennsylvania
University of Tennessee Medical Center
Knoxville, Tennessee
Tennessee Oncology - Centennial Clinic Location
Nashville, Tennessee
Verdi Oncology
Nashville, Tennessee
UT Southwestern Medical Center
Dallas, Texas
Intermountain Medical Center
Murray, Utah
University of Virginia Medical Center
Charlottesville, Virginia
DIABAID - Instituto de Asistencia Integral en Diabetes
Caba, Argentina
Fundacion Centro de Investigaciones para la Transformacion (CENIT)
Caba, Buenos Aires, Argentina
Centro de Investigacion Pergamino
Pergamino, Buenos Aires, Argentina
Clinica Viedma S.A.
Viedma, Río Negro Province, Argentina
Instituto de Oncologia de Rosario
Rosario, Santa Fe Province, Argentina
Centro Medico San Roque
San Miguel de Tucumán, Tucumán Province, Argentina
Blacktown Cancer and Haematology Centre - Blacktown Hospital
Blacktown, New South Wales, Australia
Lismore Base Hospital
Lismore, New South Wales, Australia
Liverpool Hospital - Cancer Therapy Centre
Liverpool, New South Wales, Australia
Melanoma Institute of Australia
Wollstonecraft, New South Wales, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Calvary North Adelaide Hospital
North Adelaide, South Australia, Australia
Showing 40 of 211 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.